EA200100703A1 - Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных никотиновой кислоты для сердечно-сосудистых показаний - Google Patents

Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных никотиновой кислоты для сердечно-сосудистых показаний

Info

Publication number
EA200100703A1
EA200100703A1 EA200100703A EA200100703A EA200100703A1 EA 200100703 A1 EA200100703 A1 EA 200100703A1 EA 200100703 A EA200100703 A EA 200100703A EA 200100703 A EA200100703 A EA 200100703A EA 200100703 A1 EA200100703 A1 EA 200100703A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combinations
transport
nucotinic
bilk
subjective
Prior art date
Application number
EA200100703A
Other languages
English (en)
Other versions
EA005030B1 (ru
Inventor
Брэдли Т. КЕЛЛЕР
Кевин К. Гленн
Дэниел Т. Коннолли
Original Assignee
Джи.Ди.Сирл Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200100703(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джи.Ди.Сирл Ллс filed Critical Джи.Ди.Сирл Ллс
Publication of EA200100703A1 publication Critical patent/EA200100703A1/ru
Publication of EA005030B1 publication Critical patent/EA005030B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение предоставляет сочетания сердечно-сосудистых терапевтических соединений, предназначенных для профилактики или лечения сердечно-сосудистого заболевания, включая гиперхолестеринемию, атеросклероз или гиперлипидемию. Раскрытые сочетания включают ингибитор транспорта желчных кислот в подвздошной кишке вместе с производным никотиновой кислоты.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100703A 1998-12-23 1999-12-17 Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных никотиновой кислоты, фармкомпозиция и способ профилактики и лечения гиперлипидемических состояний EA005030B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11395598P 1998-12-23 1998-12-23
US14255099P 1999-07-07 1999-07-07
PCT/US1999/027950 WO2000038729A1 (en) 1998-12-23 1999-12-17 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications

Publications (2)

Publication Number Publication Date
EA200100703A1 true EA200100703A1 (ru) 2001-12-24
EA005030B1 EA005030B1 (ru) 2004-10-28

Family

ID=26811675

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100703A EA005030B1 (ru) 1998-12-23 1999-12-17 Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных никотиновой кислоты, фармкомпозиция и способ профилактики и лечения гиперлипидемических состояний

Country Status (25)

Country Link
US (1) US20030125316A1 (ru)
EP (1) EP1140191B1 (ru)
JP (1) JP2002533415A (ru)
KR (1) KR20010102963A (ru)
CN (1) CN1338946A (ru)
AR (1) AR037806A1 (ru)
AT (1) ATE226448T1 (ru)
AU (1) AU776952B2 (ru)
BR (1) BR9916567A (ru)
CA (1) CA2356664A1 (ru)
CZ (1) CZ20012343A3 (ru)
DE (1) DE69903661T2 (ru)
DK (1) DK1140191T3 (ru)
EA (1) EA005030B1 (ru)
ES (1) ES2188285T3 (ru)
HK (1) HK1044472A1 (ru)
HU (1) HUP0104593A3 (ru)
IL (1) IL143938A0 (ru)
MX (1) MXPA01006467A (ru)
MY (1) MY121399A (ru)
NO (1) NO20013160L (ru)
NZ (1) NZ512533A (ru)
PL (1) PL348581A1 (ru)
PT (1) PT1140191E (ru)
WO (1) WO2000038729A1 (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
ATE349214T1 (de) 2001-09-08 2007-01-15 Astrazeneca Ab Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
HUE030062T2 (en) 2010-11-08 2017-04-28 Albireo Ab IBAT inhibitors for the treatment of liver diseases
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ppar活性化剤
HUE053359T2 (hu) * 2012-06-15 2021-06-28 Conaris Res Institute Ag Nikotinsavat és/vagy nikotinamidot és/vagy triptofánt tartalmazó gyógyászati készítmény a bél mikrobiótájának pozitív befolyásolására
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PE20210182A1 (es) 2018-06-20 2021-01-29 Albireo Ab Modificaciones de cristales de odexibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CN113453753A (zh) 2019-02-06 2021-09-28 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114761080A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114761018A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
KR20220109450A (ko) 2019-12-04 2022-08-04 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
EP4069359B1 (en) * 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
ES2188285T3 (es) 2003-06-16
HUP0104593A2 (hu) 2002-03-28
PL348581A1 (en) 2002-06-03
EA005030B1 (ru) 2004-10-28
NO20013160D0 (no) 2001-06-22
CZ20012343A3 (cs) 2001-12-12
HK1044472A1 (zh) 2002-10-25
NO20013160L (no) 2001-08-21
EP1140191A1 (en) 2001-10-10
WO2000038729A1 (en) 2000-07-06
US20030125316A1 (en) 2003-07-03
DE69903661D1 (de) 2002-11-28
IL143938A0 (en) 2002-04-21
CN1338946A (zh) 2002-03-06
MXPA01006467A (es) 2004-03-10
DK1140191T3 (da) 2003-02-24
BR9916567A (pt) 2001-12-11
DE69903661T2 (de) 2003-07-03
HUP0104593A3 (en) 2004-10-28
PT1140191E (pt) 2003-01-31
CA2356664A1 (en) 2000-07-06
MY121399A (en) 2006-01-28
ATE226448T1 (de) 2002-11-15
NZ512533A (en) 2004-02-27
EP1140191B1 (en) 2002-10-23
KR20010102963A (ko) 2001-11-17
AU776952B2 (en) 2004-09-30
JP2002533415A (ja) 2002-10-08
AU2348100A (en) 2000-07-31
AR037806A1 (es) 2004-12-09

Similar Documents

Publication Publication Date Title
EA200100703A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных никотиновой кислоты для сердечно-сосудистых показаний
EA200100707A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных фибриновой кислоты для сердечно-сосудистых показаний
EA200100702A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
EA200100705A1 (ru) Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний
DK1140184T3 (da) Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
EA200100704A1 (ru) Комбинация для применения по сердечно-сосудистым показаниям
EA199900837A1 (ru) Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств
EA200300914A1 (ru) Сочетание ингибиторов белка, переносящего эфир холестерила, и производных фибриновой кислоты для сердечно-сосудистых показаний
EA200001140A1 (ru) СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
DK1140185T3 (da) Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU